GREENWICH LIFESCIENCES, INC. Increase (Decrease) in Interest Payable, Net
GREENWICH LIFESCIENCES, INC. (GLSI) reported Increase (Decrease) in Interest Payable, Net of $36.61 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2023-03-31
- GREENWICH LIFESCIENCES, INC. increase (decrease) in interest payable, net for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in interest payable, net for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in interest payable, net for the quarter ending 2021-06-30 was $18.30K, a 0.01% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in interest payable, net for the quarter ending 2021-03-31 was $18.30K, a 0.00% change year-over-year.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in interest payable, net for fiscal 2021 was $36.61K, a 50.00% decline from fiscal 2020.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in interest payable, net for fiscal 2020 was $73.21K, a 23.35% increase from fiscal 2019.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in interest payable, net for fiscal 2019 was $59.35K.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $18.30K derived: sum of 3 quarters · filed 2023-03-31 | $36.61K 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $18.30K derived: sum of 2 quarters · filed 2022-11-14 | $36.61K 10-Q · filed 2022-11-14 | $54.91K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $18.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $36.61K 10-Q · filed 2022-08-15 | $54.91K derived: sum of 3 quarters · filed 2022-08-15 | $73.21K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $18.30K 10-Q · filed 2022-05-20 | $36.60K derived: sum of 2 quarters · filed 2022-05-20 | $54.91K derived: sum of 3 quarters · filed 2022-05-20 | $73.21K derived: sum of 4 quarters · filed 2022-05-20 |
| 2020-12-31 | $18.30K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $36.60K derived: sum of 2 quarters · filed 2022-03-21 | $54.91K derived: sum of 3 quarters · filed 2022-03-21 | $73.21K 10-K · filed 2022-03-21 |
| 2020-09-30 | $18.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $36.61K derived: sum of 2 quarters · filed 2021-11-15 | $54.91K 10-Q · filed 2021-11-15 | $71.66K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $18.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $36.61K 10-Q · filed 2021-08-13 | $53.36K derived: sum of 3 quarters · filed 2021-08-13 | |
| 2020-03-31 | $18.30K 10-Q · filed 2021-05-20 | $35.06K derived: sum of 2 quarters · filed 2021-05-20 | ||
| 2019-12-31 | $16.75K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $59.35K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $42.60K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |